Lilly reports 28% weight loss with new obesity drug

• Retatrutide produced weight loss comparable to bariatric surgery, with patients on extended two-year treatment losing just over 30% of their weight on average
• The drug activates three hormone receptors (GLP-1, GIP, and glucagon) and has shown superior weight loss results compared to Lilly's and Novo Nordisk's other obesity medications
• Side effects included dysesthesia (abnormal skin sensation) in 12.5% of patients on the 12mg dose versus 0.9% with placebo, though Lilly stated side effects were on par with other GLP-1 medications

Eli Lilly Reports Breakthrough Weight Loss Results with Experimental Obesity Drug

Eli Lilly announced Thursday that its experimental obesity drug retatrutide demonstrated 28.3% average weight loss in patients over 80 weeks in a late-stage trial, paving the way for regulatory approval and a planned 2024 launch.

Key Trial Results:

• Patients on the highest 12mg dose lost an average of 28.3% of their weight over 80 weeks
• Over 45% of participants lost 30% or more of their body weight
• Lower 4mg dose resulted in 19% weight loss
• Extended two-year use showed over 30% average weight loss
• Results aligned with analyst expectations of 28-30% weight loss

Drug Profile:

Retatrutide is a "triple G" medication that activates three hormone receptors: GLP-1 (appetite suppression), GIP (insulin secretion), and glucagon (fat burning). This mechanism has demonstrated superior weight loss compared to existing treatments from Lilly and competitor Novo Nordisk, including Zepbound and Wegovy.

Market Context:

The trial participants had obesity or were overweight with at least one weight-related comorbidity, but not diabetes. Kenneth Custer, Lilly's president of cardiometabolic health, noted the 30% weight loss threshold historically associated with bariatric surgery represents a significant breakthrough for pharmaceutical intervention.

Safety Concerns:

Dysesthesia (abnormal skin sensation) occurred in 12.5% of patients on the 12mg dose versus 0.9% with placebo. JPMorgan analysts previously noted higher side effect incidences compared to Lilly's diabetes drug Mounjaro, though company officials stated side effects were comparable to other GLP-1 medications.

Previous trials showed promising results in osteoarthritis patients and diabetics, reinforcing retatrutide's position in the competitive obesity medication market.